BUSCADOR RECOLECTA

MicroRNAs (miRs) have emerged as promising biomarkers for early disease diagnosis and personalised treatment monitoring. However, but their clinical utility has been hampered by technical limitations. Dynamic chemical labelling (DCL) based on capturing abasic PNA probes and reactive nucleobases, so-called SMART bases, is a PCR-free approach that has proven very useful for the direct interrogation of circulating miRs. In this work, we expand the palette of available tools for DCL miR detection methods with a newly synthesised SMART nucleobase, SMART-C-Eu. This nucleobase contains a stable lanthanide cryptate. Using this SMART-C-Eu base and time-gated (TG) luminescence imaging, we successfully detect and quantify miR-122-5p in human serum samples. miR-122-5p is a well-known biomarker for drug-induced liver injury. A bead-counting analysis approach improved statistical robustness and allowed the detection of miR-122-5p concentrations in the nanomolar range. Furthermore, we extend this approach to multiplexed detection of three different miRs (miR-371a-3p, miR-451a-5p, and miR-122-5p) using spectral and temporal filtering. Consistent results were obtained using machine learning algorithms for automatic bead classification. Although this technique requires further sensitivity improvements to detect miRs at lower concentrations, it represents a significant advancement in miR analysis. It offers multiplexing capabilities and the potential for automation, paving the way for more accurate and robust clinical applications in the future., European Union through the H2020 diaRNAgnosis project, under grant agreement No. 101007934, Agencia Estatal de Investigación (Spain) through grant PID2020-114256RB-I00 AEI/10.13039/501100011033, Agencia Estatal de Investigación (Spain) through grant CTQ2017-85658-R AEI/10.13039/501100011033/FEDER “Una manera de hacer Europa”.

This work was supported by grant CTQ2017-85658-R funded by MCIN/AEI/10.13039/501100011033/ FEDER “Una manera de hacer Europa”, grant PID2020-114256RB-I00 funded by MCIN/AEI/10.13039/501100011033, and the diaRNAgnosis project funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 101007934. P.M.R.P. acknowledges funding from Fundação para a Ciência e a Tecnologia, I.P., through projects UIDB/00100/2020 and 2022.04076.PTDC., Controlling the nano- and micropatterning of metal structures is an important requirement for various technological applications in photonics and biosensing. We present a method for controllably creating silver micropatterns by laser-induced photo-sculpting. Photo-sculpting is driven by plasmonic interactions between pulsed laser radiation and silver nanorods (AgNRs) in aqueous suspension; this process leads to optical binding forces transporting the AgNRs in the surroundings, while electronic thermalization results in photooxidation, melting, and ripening of the AgNRs into well-defined 3D structures. We called these structures Airy castles due to their structural similarity with a diffraction-limited Airy disk. The photo-sculpted Airy castles contain emissive Ag nanoclusters, allowing for the visualization and examination of the aggregation process using luminescence microscopy. We comprehensively examine the factors that define the photo-sculpting process, namely, the concentration and shape of the AgNRs, as well as the energy, power and repetition rate of the laser. Finally, we investigate the potential applications by measuring the metal-enhanced luminescence of a europium-based luminophore using Airy castles., Grant CTQ2017-85658-R funded by MCIN/AEI/10.13039/501100011033/ FEDER “Una manera de hacer Europa”, Grant PID2020-114256RB-I00 funded by MCIN/AEI/10.13039/501100011033, diaRNAgnosis project funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 101007934, Fundação para a Ciência e a Tecnologia, I.P., through projects UIDB/00100/2020 and 2022.04076.PTDC

PROYECTO DE INVESTIGACION DE EXCELENCIA DE LA JUNTA DE ANDALUCIA, DE TITULO ALHAMAT: La Alhambra material: foco del poder en el territorio nazarí (ref. P18-FR-4173), LA UNIDAD DE EXCELENCIA DE LA UGR "CIENCIA EN LA ALHAMBRA" (UCE-PP2018-01)

Proyecto Multi-methodological Approach to Residential Behaviour and Everyday Life, MARBEL (PID2020-119569GA-I00). Financiado por Ministerio de Ciencia e Innovación, Gobierno de España

[Organism] Rattus norvegicus, [Experiment type] Expression profiling by array, [Overall design] Breast tumors were induced with a single oral dosage of 7,12-dimethylbenz(alpha)anthracene (100 mg/kg body weight) in female Sprague-Dawley rats and subsequently treated with adriamycin (1 mg/kg body weight/week for 6 weeks) intravenously through lateral tail vein. Gene expression analysis was performed in paired samples as follows: ADR final trucut tumor vs initial trucut tumor (ADR final vs basal). For this assay, 5 samples were chosen according to histopathologic criteria (Bloom-Richardson grade II). Gene expression profiling was carried out using Affymetrix’s GeneChip technology, using the Rat Genome 230 2.0 array from this provider. All the protocols and apparatus were recommended by Affymetrix. Total RNA from frozen mammary tumors was extracted by RNeasy Mini kit and homogenized by QIAshredder columns according to manufacturer’s instructions. The quality and quantity of the obtained RNA was checked out through agarose electrophoresis and later spectrophotometry at 260/280 nm. Biotinylated cRNA was synthesized following the IVT labeling kit from Affymetrix and purified by the GeneChip Sample Cleanup Module from Affymetrix. The quality and quantity of the obtained cRNA was again checked out through agarose electrophoresis and posterior spectrophotometry at 260/280 nm. After hybridization, slides were washed and scanned following the manufacturer’s standard protocol. Intensity values were normalized by Robust Multichip Average method and subsequently these were filtered to remove the control sequences and those with a hybridization signal close to background. The spike controls were: BioB, BioC, BioD and Cre; because BioB was the least abundant in the samples, it was used to estimate the sensitivity of the experiment. The housekeeping control was GAPDH. After non-supervised clustering using Pearson correlation coefficient, statistical significance of gene expression was estimated by Student’s T test for paired samples, using GeneSpring GX 7.3 software (Agilent)., 1. GSM399913 Breast tumor biopsy_adriamycin_07SE125. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with adriamycin. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 09I1 (basal), 2. GSM399914 Total breast tumor_ adriamycin _07SE140. [Characteristics strain: ]Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: adriamycin (1 mg/kg weight/week, for 6 weeks) through the lateral tail vein after trucut biopsy. sacrifice: 7th week post-biopsy sample: 09I1 (final), 3. GSM399915 Breast tumor biopsy_adriamycin_07SE126. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with adriamycin. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 11D2 (basal), 4. GSM399916 Total breast tumor_ adriamycin _07SE141. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: adriamycin (1 mg/kg weight/week, for 6 weeks) through the lateral tail vein after trucut biopsy. sacrifice: 7th week post-biopsy sample: 11D2 (final), 5. GSM399949 Breast tumor biopsy_adriamycin_07SE127. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with adriamycin. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 12I1 (basal), 6. GSM399959 Total breast tumor_ adriamycin _07SE142. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: adriamycin (1 mg/kg weight/week, for 6 weeks) through the lateral tail vein after trucut biopsy. sacrifice: 7th week post-biopsy sample: 12I1 (final), 7. GSM399960 Breast tumor biopsy_adriamycin_07SE128. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with adriamycin. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 29I1 (basal), 8. GSM399961 Total breast tumor_ adriamycin _07SE143. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: adriamycin (1 mg/kg weight/week, for 6 weeks) through the lateral tail vein after trucut biopsy. sacrifice: 7th week post-biopsy sample: 29I1 (final), 9. GSM399980 Breast tumor biopsy_adriamycin_07SE129. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with adriamycin. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 43D1 (basal), 10. GSM399981 Total breast tumor_ adriamycin _07SE144. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: adriamycin (1 mg/kg weight/week, for 6 weeks) through the lateral tail vein after trucut biopsy. sacrifice: 7th week post-biopsy sample: 43D1 (final), The aim of this study was to compare the gene expression profile changes of DMBA-induced rat breast tumors after treatment with adriamycin. To this end, a cDNA microarray was performed (Affymetrix’s Rat Genome 230 2.0 array). This gene expression study was carried out on the tumor biopsy samples prior to adriamycin treatment, and compared with matched tumor biopsy samples after completion of the adriamycin treatment schedule.

[Organism] Rattus norvegicus, [Experiment type] Expression profiling by array, [Overall design] Breast tumors were induced with a single oral dose of 7,12-dimethylbenz(alpha)anthracene (100 mg/kg body weight) in female Sprague-Dawley rats to test the antitumor power of orally administrated hydroxytyrosol (0.5 mg/kg body weight 5 days/week for 6 weeks). Gene expression analysis was performed in paired samples as follows: HT final trucut tumor vs initial trucut tumor (HT final vs basal). For this assay, 5 samples were chosen according to histopathologic criteria (Bloom-Richardson grade II). Gene expression profiling was carried out using Affymetrix’s GeneChip technology, using the Rat Genome 230 v2.0 array from this provider. All the protocols and apparatus were recommended by Affymetrix. Total RNA from frozen mammary tumors was extracted by RNeasy Mini kit and homogenized by QIAshredder columns according to manufacturer’s instructions. The quality and quantity of the obtained RNA was checked out through agarose electrophoresis and later spectrophotometry at 260/280 nm. Biotinylated cRNA was synthesized following the IVT labeling kit from Affymetrix and purified by the GeneChip Sample Cleanup Module from Affymetrix. The quality and quantity of the obtained cRNA was again checked out through agarose electrophoresis and posterior spectrophotometry at 260/280 nm. After hybridization, slides were washed and scanned following the manufacturer’s standard protocol. Intensity values were normalized by Robust Multichip Average method and subsequently these were filtered to remove the control sequences and those with a hybridization signal close to background. The spike controls were: BioB, BioC, BioD and Cre; because BioB was the least abundant in the samples, it was used to estimate the sensitivity of the experiment. The housekeeping control was GAPDH. After non-supervised clustering using Pearson correlation coefficient, statistical significance of gene expression was estimated by Student’s T test for paired samples using GeneSpring GX 7.3 software (Agilent)., [Platforms (1)] GPL1355 [Rat230_2] Affymetrix Rat Genome 230 2.0 Array, [Relations] BioProject PRJNA116997, 1. GSM399469 Breast tumor biopsy_hydroxytyrosol_07SE120. [Source name] Breast tumor biopsy, hydroxytyrosol, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with hydroxytyrosol. Such biopsy was taken when tumor had 2cm3 volume biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 66D2 (basal), 2. GSM399474 Total breast tumor_hydroxytyrosol_07SE135. [Source name] Total breast tumor, hydroxytyrosol, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: hydroxytyrosol (0,5 mg/kg weight/day, 5 days/week, for 6 weeks) by gavage after trucut biopsy. sacrifice: 7th week post-biopsy sample: 66D2 (final), 3. GSM399475 Breast tumor biopsy_hydroxytyrosol_07SE121. [Source name] Breast tumor biopsy, hydroxytyrosol, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with hydroxytyrosol. Such biopsy was taken when tumor had 2cm3 volume biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 67D3(basal), 4. GSM399476 Total breast tumor_hydroxytyrosol_07SE136. [Source name] Total breast tumor, hydroxytyrosol, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: hydroxytyrosol (0,5 mg/kg weight/day, 5 days/week, for 6 weeks) by gavage after trucut biopsy. sacrifice: 7th week post-biopsy sample: 67D3 (final), 5. GSM399477 Breast tumor biopsy_hydroxytyrosol_07SE122. [Source name] Breast tumor biopsy, hydroxytyrosol, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with hydroxytyrosol. Such biopsy was taken when tumor had 2cm3 volume biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 45D3 (basal), 6. GSM399478 Total breast tumor_hydroxytyrosol_07SE137. [Source name] Total breast tumor, hydroxytyrosol, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: hydroxytyrosol (0,5 mg/kg weight/day, 5 days/week, for 6 weeks) by gavage after trucut biopsy. sacrifice: 7th week post-biopsy sample: 45D3 (final), 7. GSM399892 Breast tumor biopsy_hydroxytyrosol_07SE123. [Source name] Breast tumor biopsy, hydroxytyrosol, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with hydroxytyrosol. Such biopsy was taken when tumor had 2cm3 volume biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 49I1 (basal), 8. GSM399893 Total breast tumor_hydroxytyrosol_07SE138. [Source name] Total breast tumor, hydroxytyrosol, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: hydroxytyrosol (0,5 mg/kg weight/day, 5 days/week, for 6 weeks) by gavage after trucut biopsy. sacrifice: 7th week post-biopsy sample: 49I1 (final), 9. GSM399894 Breast tumor biopsy_hydroxytyrosol_07SE124. [Source name] Breast tumor biopsy, hydroxytyrosol, basal moment . [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene before treatment with hydroxytyrosol. Such biopsy was taken when tumor had 2cm3 volume biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 51I1 (basal), 10. GSM399912 Total breast tumor_hydroxytyrosol_07SE139. [Source name] Total breast tumor, hydroxytyrosol, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: hydroxytyrosol (0,5 mg/kg weight/day, 5 days/week, for 6 weeks) by gavage after trucut biopsy. sacrifice: 7th week post-biopsy sample: 51I1 (final), The aim of this study was to compare the gene expression profile changes of DMBA-induced rat breast tumors after treatment with hydroxytyrosol (a natural compound from virgin olive oil). To this end, a cDNA microarray experiment was performed (Affymetrix’s Rat Genome 230 2.0 array). This gene expression study was carried out on the tumor biopsy samples prior to hydroxytyrosol treatment, and compared with matched tumor biopsy samples after completion of the hydroxytyrosol treatment schedule. The result of this study was the identification of several genes related to apoptosis, cell cycle arrest, proliferation, differentiation, survival and transformation-related genes.

[Organism] Rattus norvegicus, [Experiment type] Expression profiling by array, [Overall design] Breast tumors were induced with a single oral dosage of 7,12-dimethylbenz(alpha)anthracene (100 mg/kg body weight) in female Sprague-Dawley rats. Gene expression analysis was performed in paired samples as follows: DMBA final trucut tumor vs initial trucut tumor (DMBA final vs basal). For this assay, 5 samples were chosen according to histopathologic criteria (Bloom-Richardson grade II). Gene expression profiling was carried out using Affymetrix’s GeneChip technology, using the Rat Genome 230 2.0 array from this provider. All the protocols and apparatus were recommended by Affymetrix. Total RNA from frozen mammary tumors was extracted by RNeasy Mini kit and homogenized by QIAshredder columns according to manufacturer’s instructions. The quality and quantity of the obtained RNA was checked out through agarose electrophoresis and later spectrophotometry at 260/280 nm. Biotinylated cRNA was synthesized following the IVT labeling kit from Affymetrix and purified by the GeneChip Sample Cleanup Module from Affymetrix. The quality and quantity of the obtained cRNA was again checked out through agarose electrophoresis and posterior spectrophotometry at 260/280 nm. After hybridization, slides were washed and scanned following the manufacturer’s standard protocol. Intensity values were normalized by Robust Multichip Average method and subsequently these were filtered to remove the control sequences and those with a hybridization signal close to background. The spike controls were: BioB, BioC, BioD and Cre; because BioB was the least abundant in the samples, it was used to estimate the sensitivity of the experiment. The housekeeping control was GAPDH. After non-supervised clustering using Pearson correlation coefficient, statistical significance of gene expression was estimated by Student’s T test for paired samples, using GeneSpring GX 7.3 software (Agilent)., [Platforms (1)] GPL1355 [Rat230_2] Affymetrix Rat Genome 230 2.0 Array, [Relations] BioProject PRJNA115167, 1. GSM398893 Breast tumor biopsy_DMBA_07SE115. [Source name] Breast tumor biopsy, DMBA, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 31D3 (basal), 2. GSM398894 Total breast tumor_DMBA_07SE130. [Source name] Total breast tumor, DMBA, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: none sample: 31D3 (final), 3. GSM399028 Breast tumor biopsy_DMBA_07SE116. [Source name] Breast tumor biopsy, DMBA, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 32D1 (basal)., 4. GSM399030 Total breast tumor_DMBA_07SE131. [Source name] Total breast tumor, DMBA, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: none sample: 32D1 (final), 5. GSM399430 Breast tumor biopsy_DMBA_07SE117. [Source name] Breast tumor biopsy, DMBA, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 37I1 (basal), 6. GSM399433 Total breast tumor_DMBA_07SE132. [Source name] Total breast tumor, DMBA, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: none sample: 37I1 (final), 7. GSM399434 Breast tumor biopsy_DMBA_07SE118. [Source name] Breast tumor biopsy, DMBA, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 50I1 (basal), 8. GSM399456 Total breast tumor_DMBA_07SE133. [Source name] Total breast tumor, DMBA, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: none sample: 50I1 (final), 9. GSM399460 Breast tumor biopsy_DMBA_07SE119. [Source name] Breast tumor biopsy, DMBA, basal moment. [Characteristics] strain: Sprague-Dawley gender: female age: 12 weeks tissue: Breast tumor. Trucut Biopsy of breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene. Such biopsy was taken when tumor had 2cm3 volume. biopsy dimensions: 0.7 cm x 2.5 mm treatment: none sample: 52I4 (basal), 10. GSM399466 Total breast tumor_DMBA_07SE134. [Source name] Total breast tumor, DMBA, final moment. [Characteristics] strain: Sprague-Dawley gender: female age: 19 weeks tissue: Breast tumor. Breast tumor chemically induced with 7,12-dimethylbenz(a)anthracene at the moment of sacrifice. treatment: none sample: 52I4(final), The aim of this study was to compare the gene expression profile changes of DMBA-induced rat breast tumors from an initial stage to the moment of sacrifice. To this end, a cDNA microarray was performed (Affymetrix’s Rat Genome 230 2.0 array). This gene expression study was carried out on the umor biopsy samples and compared with matched tumor biopsy samples once the study ended (7 weeks after initial biopsy).